ReviewOncotarget2017
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy.Obesity surgery · 2024Pooled it
- Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance.Biomedicines · 2026Review
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma.Medicina (Kaunas, Lithuania) · 2025Article
- The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients.Biomedicines · 2023Article
- Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system.STAR protocols · 2022Article
- Review
- Immunological Prognostic Factors in Multiple Myeloma.International journal of molecular sciences · 2021Review
- The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.International journal of molecular sciences · 2020Article
- Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.International journal of molecular sciences · 2020Review
- Targeting NF-κB Signaling for Multiple Myeloma.Cancers · 2020Review
- Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients.Journal of clinical medicine · 2020Review
- IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification.Haematologica · 2020Article
- Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.International journal of molecular sciences · 2020Review
- The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.Leukemia · 2020Article
- Review
- Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.Frontiers in cell and developmental biology · 2019Review
- NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.International journal of molecular sciences · 2018Review
- Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.Investigational new drugs · 2018Article
- Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.Haematologica · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the advent of many therapeutic agents, such as bortezomib and lenalidomide that have significantly improved the overall survival, multiple myeloma remains an incurable disease. Failure to cure is multifactorial and can be attributed to the underlying genetic heterogeneity of the cancer and to the surrounding micro-environment. Understanding the mutual interaction between myeloma cells and micro-environment may lead to the development of novel treatment strategies able to eradicate this disease. In this review we discuss the principal molecules involved in the micro-environment network in multiple myeloma and the currently available therapies targeting them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.